|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: METTL3 |
Gene summary for METTL3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | METTL3 | Gene ID | 56339 |
| Gene name | methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit | |
| Gene Alias | IME4 | |
| Cytomap | 14q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q86U44 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56339 | METTL3 | LZE2T | Human | Esophagus | ESCC | 2.41e-02 | 3.14e-01 | 0.082 |
| 56339 | METTL3 | LZE4T | Human | Esophagus | ESCC | 1.37e-04 | 1.21e-01 | 0.0811 |
| 56339 | METTL3 | LZE7T | Human | Esophagus | ESCC | 4.34e-02 | 1.82e-01 | 0.0667 |
| 56339 | METTL3 | LZE20T | Human | Esophagus | ESCC | 2.47e-03 | 9.59e-02 | 0.0662 |
| 56339 | METTL3 | LZE24T | Human | Esophagus | ESCC | 1.84e-13 | 2.59e-01 | 0.0596 |
| 56339 | METTL3 | P1T-E | Human | Esophagus | ESCC | 6.42e-04 | 1.76e-01 | 0.0875 |
| 56339 | METTL3 | P2T-E | Human | Esophagus | ESCC | 3.63e-15 | 1.57e-01 | 0.1177 |
| 56339 | METTL3 | P4T-E | Human | Esophagus | ESCC | 5.81e-16 | 2.79e-01 | 0.1323 |
| 56339 | METTL3 | P5T-E | Human | Esophagus | ESCC | 3.87e-07 | 1.11e-01 | 0.1327 |
| 56339 | METTL3 | P8T-E | Human | Esophagus | ESCC | 7.83e-26 | 2.33e-01 | 0.0889 |
| 56339 | METTL3 | P9T-E | Human | Esophagus | ESCC | 5.90e-07 | 1.58e-01 | 0.1131 |
| 56339 | METTL3 | P10T-E | Human | Esophagus | ESCC | 2.08e-31 | 3.88e-01 | 0.116 |
| 56339 | METTL3 | P11T-E | Human | Esophagus | ESCC | 6.72e-05 | 3.01e-01 | 0.1426 |
| 56339 | METTL3 | P12T-E | Human | Esophagus | ESCC | 1.92e-27 | 5.09e-01 | 0.1122 |
| 56339 | METTL3 | P15T-E | Human | Esophagus | ESCC | 3.79e-27 | 3.38e-01 | 0.1149 |
| 56339 | METTL3 | P16T-E | Human | Esophagus | ESCC | 1.25e-17 | 1.77e-01 | 0.1153 |
| 56339 | METTL3 | P17T-E | Human | Esophagus | ESCC | 6.20e-03 | 1.98e-01 | 0.1278 |
| 56339 | METTL3 | P20T-E | Human | Esophagus | ESCC | 2.70e-11 | 1.13e-01 | 0.1124 |
| 56339 | METTL3 | P21T-E | Human | Esophagus | ESCC | 1.66e-12 | 1.10e-01 | 0.1617 |
| 56339 | METTL3 | P22T-E | Human | Esophagus | ESCC | 8.38e-19 | 2.09e-01 | 0.1236 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00346444 | Oral cavity | OSCC | cellular response to UV | 63/7305 | 90/18723 | 2.42e-09 | 5.60e-08 | 63 |
| GO:00028317 | Oral cavity | OSCC | regulation of response to biotic stimulus | 177/7305 | 327/18723 | 1.73e-08 | 3.43e-07 | 177 |
| GO:00714788 | Oral cavity | OSCC | cellular response to radiation | 109/7305 | 186/18723 | 4.54e-08 | 8.45e-07 | 109 |
| GO:00610149 | Oral cavity | OSCC | positive regulation of mRNA catabolic process | 58/7305 | 87/18723 | 1.59e-07 | 2.61e-06 | 58 |
| GO:004211016 | Oral cavity | OSCC | T cell activation | 245/7305 | 487/18723 | 2.00e-07 | 3.22e-06 | 245 |
| GO:00987277 | Oral cavity | OSCC | maintenance of cell number | 81/7305 | 134/18723 | 3.96e-07 | 5.90e-06 | 81 |
| GO:00198276 | Oral cavity | OSCC | stem cell population maintenance | 79/7305 | 131/18723 | 6.28e-07 | 8.96e-06 | 79 |
| GO:00611579 | Oral cavity | OSCC | mRNA destabilization | 55/7305 | 84/18723 | 8.05e-07 | 1.12e-05 | 55 |
| GO:00507799 | Oral cavity | OSCC | RNA destabilization | 57/7305 | 88/18723 | 8.70e-07 | 1.19e-05 | 57 |
| GO:004851116 | Oral cavity | OSCC | rhythmic process | 157/7305 | 298/18723 | 1.00e-06 | 1.36e-05 | 157 |
| GO:00019594 | Oral cavity | OSCC | regulation of cytokine-mediated signaling pathway | 87/7305 | 150/18723 | 1.82e-06 | 2.35e-05 | 87 |
| GO:00094511 | Oral cavity | OSCC | RNA modification | 95/7305 | 167/18723 | 2.05e-06 | 2.62e-05 | 95 |
| GO:00603384 | Oral cavity | OSCC | regulation of type I interferon-mediated signaling pathway | 28/7305 | 36/18723 | 2.45e-06 | 3.08e-05 | 28 |
| GO:00607594 | Oral cavity | OSCC | regulation of response to cytokine stimulus | 92/7305 | 162/18723 | 3.25e-06 | 3.90e-05 | 92 |
| GO:00028324 | Oral cavity | OSCC | negative regulation of response to biotic stimulus | 65/7305 | 108/18723 | 6.62e-06 | 7.29e-05 | 65 |
| GO:19031316 | Oral cavity | OSCC | mononuclear cell differentiation | 210/7305 | 426/18723 | 8.44e-06 | 9.02e-05 | 210 |
| GO:00420635 | Oral cavity | OSCC | gliogenesis | 154/7305 | 301/18723 | 1.10e-05 | 1.14e-04 | 154 |
| GO:00450884 | Oral cavity | OSCC | regulation of innate immune response | 116/7305 | 218/18723 | 1.36e-05 | 1.37e-04 | 116 |
| GO:002240718 | Oral cavity | OSCC | regulation of cell-cell adhesion | 218/7305 | 448/18723 | 1.71e-05 | 1.68e-04 | 218 |
| GO:00459482 | Oral cavity | OSCC | positive regulation of translational initiation | 23/7305 | 30/18723 | 3.05e-05 | 2.79e-04 | 23 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| METTL3 | SNV | Missense_Mutation | c.1177N>G | p.Met393Val | p.M393V | Q86U44 | protein_coding | deleterious(0) | possibly_damaging(0.78) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| METTL3 | SNV | Missense_Mutation | c.1522N>G | p.Arg508Gly | p.R508G | Q86U44 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A1KF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| METTL3 | deletion | Frame_Shift_Del | novel | c.1626delN | p.Asn543ThrfsTer15 | p.N543Tfs*15 | Q86U44 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| METTL3 | SNV | Missense_Mutation | c.1495N>A | p.Asp499Asn | p.D499N | Q86U44 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| METTL3 | SNV | Missense_Mutation | c.656N>T | p.Ser219Leu | p.S219L | Q86U44 | protein_coding | tolerated(0.1) | benign(0.021) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR | |
| METTL3 | SNV | Missense_Mutation | novel | c.52N>G | p.Leu18Val | p.L18V | Q86U44 | protein_coding | deleterious(0) | possibly_damaging(0.891) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| METTL3 | SNV | Missense_Mutation | novel | c.341N>G | p.Asp114Gly | p.D114G | Q86U44 | protein_coding | tolerated(0.37) | benign(0) | TCGA-A6-3807-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Ancillary | leucovorin | SD |
| METTL3 | SNV | Missense_Mutation | c.157C>T | p.Pro53Ser | p.P53S | Q86U44 | protein_coding | tolerated(0.4) | benign(0.019) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| METTL3 | SNV | Missense_Mutation | c.1243N>T | p.Arg415Cys | p.R415C | Q86U44 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| METTL3 | SNV | Missense_Mutation | c.1217A>G | p.Tyr406Cys | p.Y406C | Q86U44 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3989-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |